HIMS: gross margin squeeze to watch at Q1 results
- Bad news: Gross margin has compressed by about 500bps in recent quarters, the cost of moving from compounded to branded drugs.
- Good news: Internal targets were nearly met: 98% of the adjusted EBITDA target and 94% of the revenue target.
- Good news: CEO pay of $22.96 million for 2025 is heavily tied to share performance, aligning interests with shareholders.
Read the full notes
HIMS CEO compensation is heavily tied to stock performance, which aligns incentives. Internal targets were nearly achieved despite a high bar. The price pullback deepens the valuation gap versus analyst consensus. Gross margin compression needs monitoring at Q1 earnings.
Executive compensation
- Dudum 2025 total
$22.96 million
- Employee median
$84,402
- Interpretation
Pay is heavily tied to stock price performance, so the CEO's interests are highly aligned with shareholders. This is a positive signal for a founder CEO.
- Ratio
272x
- Shareholder vote
The 11 June AGM will vote on the executive compensation plan.
- Source
DEF 14A proxy filing
- Structure
Base salary is flat on 2024. Most of the pay is stock options, a long-term, non-cash incentive.
Gross margin signal
- Condition
Acceptable if subscriber growth makes up for it
- Trend
Compression of about 500bps over recent quarters, noted in multiple analyses
- Watch
Q1 earnings on 11 May are the key focus. The compression is the unavoidable cost of moving from a compounded to a branded drug distribution model.
Internal targets
- Adjusted EBITDA target achievement
98%
- Disclosure
Disclosed for the first time
- Interpretation
Management sets challenging targets, not ones that are easy to beat, and nearly fully achieved them.
- Revenue target achievement
94%
Price action
- Analyst consensus target
about $32.53
- Change
-5.30%
- 29 Apr close
$26.43
- Most bearish
Morgan Stanley, $21
- Most bullish
JPMorgan, $35 (Overweight)
- 25 Apr peak
$31
- Pullback drivers
The overhang from the Amazon One Medical narrative, plus risk-off sentiment ahead of earnings.
- Pullback from peak
-14.7%
- Upside from current price
about 23%
Q1 earnings preview
- Date
11 May 2026 (after market close)
- Days to earnings
11
- EPS estimate
$0.06 (YoY -70%)
- Key items to watch
- Subscriber growth
- Gross margin trajectory
- Progress in the transition to branded drugs
- Outlook for the peptide business
- Revenue estimate
$621 million (YoY +6%)
Sources 1
- DEF 14A proxy filing, analyst consensus data, market data for 29 Apr 2026